Palisade Bio, Inc.
PALIHealthcare|Biotechnology|US
$1.13
-0.03 (-2.59%)
DCF Value
$2.39
Tangible Book / Share
$0.58
Cash / Share
$0.59
Financials
Financial Snapshot
Market Cap
$196.9M
Enterprise Value
$71.8M
Revenue (TTM)
$500.0K
Net Income (TTM)
-$31.9M
Cash & Investments
$125.2M
Net Cash
$125.2M
Free Cash Flow (TTM)
-$18.2M
Operating CF (TTM)
-$18.2M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$125.2M
Quarterly Burn
$4.5M
Monthly Burn
$1.5M
Est. Runway
~27.5 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $20.2M | $11.7M | $5.8M | $5.1M | $729.0K | $10.5M | $12.4M | $12.4M | $9.8M | $133.4M | $125.2M | |
| Operating Cash Flow | -$15.6M | -$13.4M | -$7.7M | -$7.3M | -$4.8M | -$14.8M | -$13.4M | -$11.1M | -$12.2M | -$10.8M | -$18.2M | |
| Free Cash Flow | -$15.8M | -$13.5M | -$7.7M | -$7.3M | -$4.8M | -$14.8M | -$13.4M | -$11.1M | -$12.2M | -$10.8M | -$18.2M | |
| Capital Expenditure | -$161.1K | -$94.0K | -$1.7K | $0.00 | -$6.0K | $0.00 | -$10.0K | -$4.0K | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $23.7M | $5.0M | $1.8M | $6.6M | $1.9M | $24.6M | $15.3M | $11.2M | $9.6M | $134.4M | $138.0M |
R&D Spending
R&D (TTM)
$21.4M
R&D Intensity
4272.8%
R&D Growth vs Prior
+109.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.2K | $260.0K | $260.0K | $15.4K | $0.00 | $0.00 | $0.00 | $250.0K | $0.00 | $0.00 | $500.0K | |
| R&D Expense | $12.8M | $8.0M | $4.0M | $4.1M | $3.1M | $2.4M | $6.5M | $6.9M | $9.1M | $10.2M | $21.4M | |
| R&D % of Revenue | 79059.5% | 3078.5% | 1523.1% | 26380.4% | — | — | — | 2757.2% | — | — | 4272.8% | |
| SG&A | $7.0M | $5.2M | $4.4M | $4.4M | $6.1M | $9.3M | $8.8M | $6.2M | $5.8M | $7.9M | $14.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.2K | $260.0K | $260.0K | $15.4K | $0.00 | $0.00 | $0.00 | $250.0K | $0.00 | $0.00 | $500.0K | |
| Cost of Revenue | $0.00 | $0.00 | -$990.0K | $0.00 | $146.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $16.2K | $260.0K | $1.3M | $15.4K | -$146.0K | $0.00 | $0.00 | $250.0K | $0.00 | $0.00 | $500.0K | |
| R&D | $12.8M | $8.0M | $4.0M | $4.1M | $3.1M | $2.4M | $6.5M | $6.9M | $9.1M | $10.2M | $21.4M | |
| SG&A | $7.0M | $5.2M | $4.4M | $4.4M | $6.1M | $9.3M | $8.8M | $6.2M | $5.8M | $7.9M | $14.5M | |
| Operating Income | -$20.2M | -$13.2M | -$8.3M | -$8.6M | -$9.3M | -$41.9M | -$15.7M | -$13.1M | -$14.9M | -$18.1M | -$35.3M | |
| Interest Expense | $1.1M | $159.1K | $7.7K | $8.9K | $235.0K | $2.4M | $13.0K | $15.0K | $12.0K | $10.0K | $6.0K | |
| Pretax Income | -$21.1M | -$15.7M | -$4.9M | -$8.4M | -$10.3M | -$26.6M | -$14.3M | -$12.3M | -$14.4M | -$16.8M | -$31.9M | |
| Net Income | -$21.1M | -$15.7M | -$4.9M | -$8.4M | -$10.3M | -$26.6M | -$14.3M | -$12.3M | -$14.4M | -$16.8M | -$31.9M | |
| EPS (Diluted) | -126.11 | -71.34 | -18.02 | -35.18 | -186.00 | -2546.10 | -16.53 | -27.01 | -10.19 | -0.30 | -0.53 | |
| EBITDA | -$19.6M | -$15.2M | -$4.7M | -$8.2M | -$10.1M | -$24.2M | -$14.2M | -$12.3M | -$14.4M | -$16.8M | -$33.2M | |
| Shares Out. (M) | 0.01 | 0.22 | 0.27 | 0.24 | 0.24 | 0.01 | 0.88 | 0.46 | 1.42 | 55.67 | 211.38 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.2M | $6.7M | $5.8M | $5.1M | $713.0K | $10.5M | $12.4M | $12.4M | $9.8M | $133.4M | $125.2M | |
| Short-Term Investments | $5.0M | $5.0M | $0.00 | $0.00 | $16.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $20.9M | $12.4M | $6.5M | $5.6M | $896.0K | $11.5M | $14.7M | $13.3M | $10.5M | $134.2M | $127.3M | |
| Total Assets | $22.6M | $13.9M | $7.7M | $6.6M | $3.0M | $12.5M | $15.8M | $14.1M | $10.9M | $134.3M | $127.3M | |
| Total Current Liabilities | $7.3M | $1.5M | $1.1M | $1.2M | $8.1M | $2.5M | $3.0M | $2.6M | $3.2M | $4.6M | $5.2M | |
| Long-Term Debt | $0.00 | $0.00 | $535.0K | $0.00 | $94.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $11.3M | $5.4M | $1.6M | $1.5M | $10.1M | $5.1M | $3.3M | $2.7M | $3.4M | $5.0M | $5.6M | |
| Stockholders' Equity | $11.3M | $8.5M | $6.0M | $5.1M | -$7.1M | $7.4M | $12.5M | $11.3M | $7.5M | $129.4M | $121.7M | |
| Retained Earnings | -$193.0M | -$208.7M | -$213.6M | -$222.0M | -$68.0M | -$94.6M | -$109.2M | -$121.5M | -$135.9M | -$152.7M | -$172.9M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.6M | -$13.4M | -$7.7M | -$7.3M | -$4.8M | -$14.8M | -$13.4M | -$11.1M | -$12.2M | -$10.8M | -$18.2M | |
| Capital Expenditure | -$161.1K | -$94.0K | -$1.7K | $0.00 | -$6.0K | $0.00 | -$10.0K | -$4.0K | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$15.8M | -$13.5M | -$7.7M | -$7.3M | -$4.8M | -$14.8M | -$13.4M | -$11.1M | -$12.2M | -$10.8M | -$18.2M | |
| Investing Cash Flow | $2.4M | -$94.0K | $5.0M | $0.00 | -$6.0K | -$54.0K | -$10.0K | -$4.0K | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $23.7M | $5.0M | $1.8M | $6.6M | $1.9M | $24.6M | $15.3M | $11.2M | $9.6M | $134.4M | $138.0M | |
| Issuance of Stock | $28.1M | $8.7M | $1.8M | $6.6M | $1.2M | $5.2M | $14.4M | $9.4M | $8.4M | $135.3M | $138.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$4.4M | -$3.7M | -$13.8K | $36.4K | $802.0K | -$183.0K | -$790.0K | -$391.0K | -$426.0K | -$320.0K | -$382.0K | |
| Stock Based Comp. | $3.4M | $1.8M | $1.1M | $0.00 | $2.0M | $1.9M | $1.0M | $624.0K | $652.0K | $4.0M | $12.9M | |
| Net Change in Cash | $10.5M | -$8.5M | -$887.8K | -$672.2K | -$2.9M | $9.8M | $1.9M | $49.0K | -$2.6M | $123.6M | $119.8M |
Dilution Tracker
Shares outstanding grew 23350.8% over 5 years — significant dilution
Shares Outstanding
174M
5-Year Share Growth
+23350.8%
Stock Issuance (TTM)
$138.8M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.22 | 0.27 | 0.24 | 0.24 | 0.01 | 0.88 | 0.46 | 1.42 | 55.67 | 211.38 | |
| Change vs Prior % | — | 2531.5% | 24.4% | -13.1% | 0.0% | -94.7% | 6963.3% | -48.2% | 210.5% | 3831.5% | 279.7% | |
| Stock Issuance | $28.1M | $8.7M | $1.8M | $6.6M | $1.2M | $5.2M | $14.4M | $9.4M | $8.4M | $135.3M | $138.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.4M | $1.8M | $1.1M | $0.00 | $2.0M | $1.9M | $1.0M | $624.0K | $652.0K | $4.0M | $12.9M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 480.8% | 100.0% | — | — | — | 100.0% | — | — | 100.0% | |
| Operating Margin % | -124135.2% | -5082.7% | -3176.5% | -56073.8% | — | — | — | -5228.0% | — | — | -7069.8% | |
| Net Margin % | -129724.2% | -6025.4% | -1894.2% | -54254.9% | — | — | — | -4920.0% | — | — | -6388.2% | |
| EBITDA Margin % | -120620.5% | -5853.1% | -1819.6% | -53261.0% | — | — | — | -4912.4% | — | — | -6643.8% | |
| FCF Margin % | -97114.5% | -5196.2% | -2959.3% | -47133.2% | — | — | — | -4454.8% | — | — | -3638.0% | |
| ROE % | -186.0% | -184.0% | -81.4% | -162.9% | 145.4% | -361.4% | -114.3% | -108.7% | -192.7% | -13.0% | -33.5% | |
| ROA % | -93.2% | -112.8% | -64.1% | -126.9% | -341.9% | -212.7% | -90.5% | -87.5% | -132.7% | -12.5% | -25.1% | |
| ROIC % | -106.3% | -106.8% | -124.5% | -157.0% | 241.6% | -409.7% | -121.5% | -111.3% | -190.8% | -13.9% | -29.0% | |
| R&D / Revenue % | 79059.5% | 3078.5% | 1523.1% | 26380.4% | — | — | — | 2757.2% | — | — | 4272.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56.0% | 1500.4% | 0.0% | -94.1% | -100.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | |
| Gross Profit | 56.0% | 1500.4% | 380.8% | -98.8% | -1048.4% | 100.0% | 0.0% | 0.0% | -100.0% | 0.0% | |
| Operating Income | -5.3% | 34.5% | 37.5% | -4.5% | -7.7% | -350.2% | 62.4% | 16.9% | -13.7% | -21.5% | |
| Net Income | -0.8% | 25.7% | 68.6% | -69.6% | -23.6% | -157.9% | 46.4% | 13.7% | -17.4% | -16.2% | |
| EPS (Diluted) | 36.1% | 43.4% | 74.7% | -95.2% | -428.7% | -1268.9% | 99.4% | -63.4% | 62.3% | 97.1% | |
| Operating Cash Flow | 17.5% | 14.1% | 42.7% | 5.7% | 34.3% | -209.8% | 9.6% | 16.7% | -9.5% | 11.0% | |
| Free Cash Flow | 17.7% | 14.4% | 43.0% | 5.7% | 34.2% | -209.4% | 9.5% | 16.7% | -9.5% | 11.0% | |
| R&D Expense | 1.6% | -37.7% | -50.5% | 2.6% | -23.7% | -21.6% | 169.4% | 5.3% | 31.5% | 12.5% | |
| SG&A Expense | 13.2% | -26.0% | -15.6% | 1.6% | 36.2% | 53.8% | -5.8% | -29.2% | -6.5% | 35.7% | |
| Total Assets | 51.2% | -38.6% | -44.7% | -14.3% | -54.1% | 314.4% | 26.0% | -10.9% | -22.6% | 1134.8% | |
| Book Value / Share | 2795.2% | -97.1% | -43.1% | 89.1% | -171.4% | 2084.1% | -97.6% | 75.0% | -78.7% | -56.1% | |
| Debt | -53.3% | -100.0% | 0.0% | -94.3% | 392.5% | -86.0% | 103.0% | -8.7% | -54.2% | -58.0% | |
| Diluted Shares | -92.1% | 2531.5% | 24.4% | -13.1% | 0.0% | -94.7% | 6963.3% | -48.2% | 210.5% | 3831.5% |
Valuation
P/E (TTM)At Loss
P/S393.85
10Y Low / Med / High16.14 / 35425.23 / 164354.03
P/B1.96
10Y Low / Med / High0.31 / 5.50 / 3978.16
EV/EBITDAAt Loss
10Y Low / Med / High0.15 / 0.51 / 0.65
EV/Revenue143.51
10Y Low / Med / High29610.11 / 130261.06 / 163646.83
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$2.39
Tangible Book / Share
$0.58
Net Current Assets / Share
$0.70
Graham Net-Net
$0.57
Cash / Share
$0.59
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -2537.18 | -2162.24 | -1563.71 | -301.41 | -21.29 | -0.45 | -4.72 | -0.33 | -0.16 | -7.83 | -2.13 | |
| P/S Ratio | 164354.03 | 130286.73 | 29612.99 | 35425.23 | 0.00 | 0.00 | 0.00 | 16.14 | 0.00 | 0.00 | 393.85 | |
| P/B Ratio | 235.65 | 3978.16 | 1272.72 | 106.39 | -132.42 | 1.64 | 5.50 | 0.36 | 0.31 | 1.01 | 1.96 | |
| EV/EBITDA | -135.67 | -2225.51 | -1627.27 | -65.92 | -93.29 | -0.07 | -3.98 | 0.65 | 0.51 | 0.15 | -2.16 | |
| EV/Revenue | 163646.83 | 130261.06 | 29610.11 | 35111.71 | 0.00 | 0.00 | 0.00 | -32.11 | 0.00 | 0.00 | 143.51 |
Analyst Estimates & Quality
Altman Z-Score
19.62
Safe
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $500.0K | $47.7M | $81.0M |
| Net Income | -$12.8M | -$16.8M | -$20.3M |
| EPS | $-0.22 | $-0.28 | $-0.33 |
| # Analysts (EPS) | 8 | 8 | 7 |